Overview

Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

Status:
Unknown status

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

This phase II study examines the safety and efficacy of combination therapy for hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD). This study examines the safety and efficacy of combination therapy by imidapril (ACEI) or cilnidipine (CCB) in ADPKD patients whose blood pressure is not controlled under 120/80 mmHg by candesartan (ARB) alone.

Phase:

Phase 2

Details

Lead Sponsor:

Ministry of Health, Labour and Welfare, Japan

Treatments:

Angiotensin-Converting Enzyme Inhibitors
Cilnidipine
Imidapril